Efficacy of rituximab in refractory neuromyelitis optica

被引：49
|
作者：
Collongues, N. [1 ]
Brassat, D. [2 ]
Maillart, E. [3 ]
Labauge, P. [4 ]
Ouallet, J. C. [5 ]
Carra-Dalliere, C. [4 ]
Moreau, T. [6 ]
Bourre, B. [7 ]
Papeix, C. [3 ]
Brochet, B. [5 ]
Audoin, B. [8 ]
Vukusic, S. [9 ]
de Seze, J. [1 ]
Marignier, R. [9 ]
机构：
[1] Hop Hautepierre, Dept Neurol, 1 Ave Moliere, F-67200 Strasbourg, France
[2] Hop Purpan, Dept Neurol, Toulouse, France
[3] Hop La Pitie Salpetriere, Dept Neurol, Paris, France
[4] Hop Univ Montpellier, Dept Neurol, Montpellier, France
[5] Ctr Hosp Univ Bordeaux, Dept Neurol, Bordeaux, France
[6] Hop Univ Dijon, Dept Neurol, Dijon, France
[7] Hop Charles Nicolle, Dept Neurol, Rouen, France
[8] Hop Univ Marseille, Dept Neurol, Marseille, France
[9] Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, Dept Neurol, Lyon, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷 / 07期
关键词：
Neuromyelitis optica; rituximab; refractory; disability; body mass index; CHINESE PATIENTS; RELAPSE;
D O I：
10.1177/1352458515602337
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Background: Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy. Objective: The purpose of this study was to assess RTX as a maintenance therapy in RNMO. Methods: Out of a total of 305 NMO cases from a population-based cohort, 21 RNMO patients received RTX during a mean follow-up period of 31 months. Results: After RTX, 11 patients (52.3%) were relapse free, meaning that 47.7% were refractory to RTX. The mean annualized relapse rate decreased from 1.3 to 0.4 (p<0.001) and median EDSS from 5 to 3 (p=0.02). Body mass index (BMI) was predictive of EDSS worsening. Conclusions: RTX is an effective and well-tolerated treatment in RNMO. BMI could be a predictive factor for efficacy.
引用
收藏
页码：955 / 959
页数：5
相关论文
共 50 条
  • [31] Neuromyelitis optica complicating treatment of systemic lymphoma with rituximab
    Kurup, S.
    Gormley, K.
    Rudin, C.
    [J]. JOURNAL OF NEUROLOGY, 2009, 256 : S201 - S201
  • [32] Impact of rituximab on relapse rate and disability in neuromyelitis optica
    Bedi, Gurdesh S.
    Brown, Andrew D.
    Delgado, Sylvia R.
    Usmani, Nida
    Lam, Byron L.
    Sheremata, William A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (10) : 1225 - 1230
  • [33] Individualized Rituximab Treatment for Neuromyelitis Optica Spectrum Disorders
    McKeon, Andrew
    Pittock, Sean
    [J]. JAMA NEUROLOGY, 2013, 70 (09) : 1102 - 1104
  • [34] Rituximab during pregnancy in neuromyelitis optica: A case report
    Miranda-Acuna, Jahir
    Rivas-Rodriguez, Erica
    Levy, Michael
    Ansari, Mustafa
    Stone, Roslynn
    Patel, Vivek
    Amezcua, Lilyana
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (02):
  • [35] Therapeutic response to rituximab in neuromyelitis optica in a Mexican population
    Hernandez, L.
    Skromne, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S65 - S65
  • [36] Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica
    Graves, Jennifer
    Vinayagasundaram, Uma
    Mowry, Ellen M.
    Matthews, Ian R.
    Marino, Julia A.
    Cheng, Jing
    Waubant, Emmanuelle
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2014, 3 (02) : 244 - 252
  • [37] Capillary leak syndrome in neuromyelitis optica treated with rituximab
    Fuentes Fernandez, Ignacio
    Hernandez-Clares, Rocio
    Carreon Guarnizo, Ester
    Meca Lallana, Jose E.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 16 : 22 - 23
  • [38] Rituximab treatment in a patient with serologically proven neuromyelitis optica
    Karantoni, E.
    Evangelopoulos, M. E.
    Andreadou, E.
    Koutsis, G.
    Dimitrakopoulos, A.
    Sfagos, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 144 - 145
  • [39] Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders
    Ciron, J.
    Audoin, B.
    Bourre, B.
    Brassat, D.
    Durand-Dubief, F.
    Laplaud, D.
    Maillart, E.
    Papeix, C.
    Vukusic, S.
    Zephir, H.
    Marignier, R.
    Collongues, N.
    [J]. REVUE NEUROLOGIQUE, 2018, 174 (04) : 255 - 264
  • [40] Capillary leak syndrome in neuromyelitis optica treated with rituximab
    Hernandez Clares, R.
    Fuentes Fernandez, I.
    Carreon Guarnizo, E.
    Baidez Guerrero, A. E.
    Valero Lopez, G.
    Leon Hernandez, A.
    Velazquez Marin, F.
    Zamarro Parra, J.
    Meca Lallana, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 943 - 944
12345